SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc.

Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc. ("XBiotech") XBIT concerning possible violations of federal securities laws.

On April 20, 2017, XBiotech announced that the European Medicines Agency rendered a negative trend vote after meeting with the Company to discuss its marketing authorization application ("MAA") for XBiotech's candidate antibody for the treatment of colorectal cancer. The negative trend vote indicates that it is unlikely that the Committee for Medicinal Products for Human Use will vote in favor of the MAA at its formal decision vote scheduled for May. Following this news, shares of XBiotech were down more than 40% on intraday trading on April 21, 2017. To obtain additional information, go to:

http://zlk.9nl.com/xbiotech

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170421005774/en/